Veliparib

Generic Name: Veliparib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₄O

CAS Number: 912444-00-9

Unique Ingredient Identifier: 01O4K0631N

Indication: 与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors

Phase 2

Completed

Conditions: Solid Tumor Cancers

Interventions: Drug: veliparib
Drug: Temozolomide

First Posted Date: 2010-09-01

Last Posted Date: 2012-11-21

Lead Sponsor: Abbott

Target Recruit Count: 24

Registration Number: NCT01193140

Locations: 🇺🇸
Site Reference ID/Investigator# 42662, Santa Monica, California, United States
🇺🇸
Site Reference ID/Investigator# 43022, Encinitas, California, United States

ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Adult Solid Neoplasm
BRCA2 Mutation Carrier
BRCA1 Mutation Carrier

Interventions: Other: Diagnostic Laboratory Biomarker Analysis
Drug: Gemcitabine Hydrochloride
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2010-06-30

Last Posted Date: 2015-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT01154426

Locations: 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸
UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States

and more 1 locations

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Phase 2

Completed

Conditions: Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Locally Advanced Breast Carcinoma
Metastatic Breast Carcinoma
Unresectable Breast Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Veliparib

First Posted Date: 2010-06-23

Last Posted Date: 2024-11-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT01149083

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 20 locations

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Male Breast Carcinoma
Estrogen Receptor Negative
Stage IV Breast Cancer AJCC v6 and v7
HER2/Neu Negative
Recurrent Fallopian Tube Carcinoma
Triple-Negative Breast Carcinoma
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2010-06-16

Last Posted Date: 2017-12-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT01145430

Locations: 🇺🇸
Montefiore Medical Center-Einstein Campus, Bronx, New York, United States
🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States
🇺🇸
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States

and more 3 locations

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Secondary Acute Myeloid Leukemia
Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
Adult B Acute Lymphoblastic Leukemia
Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Alkylating Agent-Related Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Temozolomide
Drug: Veliparib

First Posted Date: 2010-06-09

Last Posted Date: 2024-08-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT01139970

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Phase 1

Completed

Conditions: Gastric Cancer

Interventions: Drug: Veliparib

First Posted Date: 2010-05-14

Last Posted Date: 2021-08-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 60

Registration Number: NCT01123876

Locations: 🇺🇸
Site Reference ID/Investigator# 24986, Washington, District of Columbia, United States
🇺🇸
Site Reference ID/Investigator# 24987, Scottsdale, Arizona, United States
🇺🇸
Site Reference ID/Investigator# 24985, Los Angeles, California, United States

and more 5 locations

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Hereditary Breast/Ovarian Cancer - BRCA2
Estrogen Receptor-negative Breast Cancer
Hereditary Breast/Ovarian Cancer - BRCA1
Male Breast Cancer
HER2-negative Breast Cancer
Progesterone Receptor-negative Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer
Triple-negative Breast Cancer

Interventions: Drug: veliparib
Drug: cisplatin
Drug: vinorelbine tartrate
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2010-04-15

Last Posted Date: 2017-08-10

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT01104259

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Solid Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Drug: Veliparib
Drug: Mitomycin

First Posted Date: 2009-11-20

Last Posted Date: 2016-07-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT01017640

Locations: 🇺🇸
Georgetown Cancer Treatment Center, Georgetown, Kentucky, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Primary Peritoneal Carcinoma
Metastatic Malignant Solid Neoplasm
Recurrent Fallopian Tube Carcinoma
Unresectable Solid Neoplasm
Recurrent Ovarian Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacogenomic Study
Other: Pharmacological Study
Drug: Topotecan Hydrochloride
Drug: Veliparib

First Posted Date: 2009-11-13

Last Posted Date: 2024-07-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 88

Registration Number: NCT01012817

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 12 locations

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Fallopian Tube Carcinoma
Fallopian Tube Carcinosarcoma
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Ovarian Clear Cell Adenocarcinoma
Ovarian Serous Adenocarcinoma
Ovarian Transitional Cell Carcinoma
Primary Peritoneal Serous Adenocarcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Veliparib

First Posted Date: 2009-10-05

Last Posted Date: 2021-10-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 431

Registration Number: NCT00989651

Locations: 🇺🇸
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 20 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy